• Consensus Rating: Buy
  • Consensus Price Target: $29.71
  • Forecasted Upside: 131.96%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$12.81
▼ -0.31 (-2.36%)

This chart shows the closing price for VSTM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Verastem Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VSTM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VSTM

Analyst Price Target is $29.71
▲ +131.96% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Verastem in the last 3 months. The average price target is $29.71, with a high forecast of $36.00 and a low forecast of $21.00. The average price target represents a 131.96% upside from the last price of $12.81.

This chart shows the closing price for VSTM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Verastem. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2023BTIG ResearchReiterated RatingBuy$27.00Low
11/15/2023Truist FinancialLower TargetBuy ➝ Buy$39.00 ➝ $34.00Low
9/27/2023B. RileyInitiated CoverageBuy ➝ Buy$21.00Low
8/29/2023MizuhoReiterated RatingBuy ➝ Buy$36.00Low
8/9/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$34.00 ➝ $32.00N/A
7/11/2023Truist FinancialLower Target$60.00 ➝ $39.00Low
7/3/2023Royal Bank of CanadaLower Target$36.00 ➝ $34.00Low
6/26/2023Cantor FitzgeraldBoost Target$3.00 ➝ $34.00Low
6/15/2023MizuhoUpgradeNeutral ➝ Buy$24.00 ➝ $36.00Low
5/15/2023Cantor FitzgeraldReiterated RatingOverweightLow
5/10/2023HC WainwrightLower Target$36.00 ➝ $24.00Low
3/29/2023MizuhoInitiated CoverageNeutral$24.00Low
3/15/2023Royal Bank of CanadaReiterated RatingOutperform$36.00Low
3/15/2023HC WainwrightReiterated RatingBuy$36.00Low
11/7/2022HC WainwrightLower TargetBuy$60.00 ➝ $36.00Low
10/5/2022BTIG ResearchLower TargetBuy$96.00 ➝ $60.00Low
9/7/2022Alliance Global PartnersReiterated RatingBuy$72.00Low
4/14/2022Royal Bank of CanadaInitiated CoverageOutperform$60.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/29/2022HC WainwrightReiterated RatingBuyHigh
3/9/2022Truist FinancialInitiated CoverageBuy$72.00High
9/20/2021HC WainwrightReiterated RatingBuy$60.00High
8/3/2021HC WainwrightReiterated RatingBuy$60.00Medium
8/3/2021Alliance Global PartnersReiterated RatingBuy$72.00High
7/20/2021HC WainwrightBoost TargetBuy$48.00 ➝ $60.00High
7/1/2021Alliance Global PartnersInitiated CoverageBuy$72.00Medium
5/24/2021BTIG ResearchUpgradeNeutral ➝ Buy$96.00High
5/13/2021HC WainwrightBoost TargetBuy$36.00 ➝ $48.00Low
4/8/2021Cantor FitzgeraldReiterated RatingOverweightMedium
3/19/2021HC WainwrightReiterated RatingBuyLow
5/11/2020HC WainwrightBoost TargetBuy$33.00 ➝ $36.00High
4/28/2020HC WainwrightReiterated RatingBuy$33.00High
3/16/2020HC WainwrightBoost TargetBuy$30.00 ➝ $33.00High
3/3/2020Cantor FitzgeraldBoost TargetOverweight$36.00 ➝ $72.00Low
1/9/2020HC WainwrightReiterated RatingBuy$30.00Low
8/2/2019B. RileySet TargetBuy$108.00Low
6/20/2019BTIG ResearchDowngradeBuy ➝ NeutralMedium
5/14/2019Roth CapitalLower TargetBuy$168.00 ➝ $48.00Low
5/10/2019BTIG ResearchLower TargetBuy$96.00High
5/10/2019HC WainwrightReiterated RatingBuy$30.00High
5/10/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
5/9/2019B. RileyReiterated RatingBuyHigh
4/3/2019Cantor FitzgeraldInitiated CoverageOverweight$60.00Low
3/14/2019Raymond JamesLower TargetOutperform ➝ Outperform$144.00 ➝ $72.00Medium
3/14/2019HC WainwrightLower TargetBuy$156.00 ➝ $120.00High
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/2/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
9/1/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/1/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/31/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
11/30/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
12/30/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
1/29/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/28/2024

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Verastem logo
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of avutometinib and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Read More

Today's Range

Now: $12.81
Low: $12.58
High: $13.23

50 Day Range

MA: $10.86
Low: $7.77
High: $14.07

52 Week Range

Now: $12.81
Low: $4.20
High: $15.18

Volume

155,151 shs

Average Volume

141,449 shs

Market Capitalization

$324.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Verastem?

The following Wall Street sell-side analysts have issued research reports on Verastem in the last year: B. Riley, BTIG Research, Cantor Fitzgerald, HC Wainwright, Mizuho, Royal Bank of Canada, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for VSTM.

What is the current price target for Verastem?

7 Wall Street analysts have set twelve-month price targets for Verastem in the last year. Their average twelve-month price target is $29.71, suggesting a possible upside of 135.8%. Mizuho has the highest price target set, predicting VSTM will reach $36.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $21.00 for Verastem in the next year.
View the latest price targets for VSTM.

What is the current consensus analyst rating for Verastem?

Verastem currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VSTM will outperform the market and that investors should add to their positions of Verastem.
View the latest ratings for VSTM.

What other companies compete with Verastem?

How do I contact Verastem's investor relations team?

Verastem's physical mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company's listed phone number is (781) 292-4200 and its investor relations email address is [email protected]. The official website for Verastem is www.verastem.com. Learn More about contacing Verastem investor relations.